2nd PRESTIGIO Registry meetING on HIV multidrug resistance

Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population. Faculty | Today, most people living with HIV (PLWH) with access to ART successfully achieve virological suppression,  although drug resistance is still an unsolved problem that may dramatically reduce therapeutic options for this population.

Faculty | 2nd PRESTIGIO Registry meetING on HIV multidrug...

• Daniele Armenia, Saint Camillus International University of Health Sciences, Roma;
• Stefano Bonora, Ospedale Amedeo di Savoia, Università degli Studi di Torino;
• Andrea Calcagno, Ospedale Amedeo di Savoia, Università degli Studi di Torino;
• Leonardo Calza, A.O.U. Policlinico S. Orsola-Malpighi, Bologna;
• Elisabetta Carini, IRCCS Ospedale San Raffaele, Milano;
• Antonella Castagna, IRCCS Ospedale San Raffaele Università Vita - Salute, Milano;
• Anna Maria Cattelan, Azienda Ospedale Università di Padova;
• Giovanni Cenderello, Azienda Socio Sanitaria Ligure 1, Sanremo;
•  Adriana Cervo, Azienda Ospedaliero - Universitaria Policlinico di Modena;
• Tommaso Clemente, Università Vita- Salute San Raffaele, Milano;
• Laura Comi, ASST Papa Giovanni XXIII, Bergamo;
• Mirko Compagno, Policlinico Tor Vergata, Roma;
• Giuseppe V. De Socio, Azienda Ospedaliera di Perugia;
• Steven Deeks, San Francisco General Hospital, University of California, San Francisco (USA);
• Antonio Di Biagio, Ospedale Policlinico S.Martino, IRCCS, Università degli Studi di Genova;
• Massimiliano Fabbiani, A.O.U. Senese - Università degli Studi di Siena;
• Marta Fiscon, Azienda Ulss 9 Scaligera, Verona;
• Emanuele Focà, Università degli Studi di Brescia ASST Spedali Civili di Brescia;
• Roberta Gagliardini, INMI Lazzaro Spallanzani IRCCS, Roma;
• Andrea Galli, IRCCS Ospedale San Raffaele, Milano;
• Andrea Giacomelli, ASST Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano;
• Giovanni Guaraldi, Azienda Ospedaliero - Universitaria Policlinico di Modena, Università degli Studi di Modena e Reggio Emilia, Modena;
• Filippo Lagi, Azienda Ospedaliero-Universitaria Careggi, Firenze;
• Riccardo Lolatto, IRCCS Ospedale San Raffaele, Milano;
• Giulia Marchetti, ASST Santi Paolo e Carlo, Università degli Studi di Milano;
• Maria Mazzitelli, Azienda Ospedale Università di Padova;
• Rebecka Papaioannu Borjesson, IRCCS Ospedale San Raffaele, Milano;
• Stefano Rusconi, ASST Ovest Milanese, Ospedale Civile di Legnano, Università degli Studi di Milano;
• Francesco Saladini, Università degli Studi di Siena;
• Pierluigi Francesco Salvo, Università Cattolica del Sacro Cuore, Roma;
• Maria Santoro, Università degli Studi di Roma Tor Vergata, Roma;
• Vincenzo Spagnuolo, IRCCS Ospedale San Raffaele, Milano;
• Anne Marie J. Wensing, University Medical Center, Utrecht (NL);
• Maurizio Zazzi, Università degli Studi di Siena.